Bottom line
How much do FBDIX and BIB overlap?
32% of their top holdings overlap by weight. 8 securities appear in both funds' top 25, making up 26.9% of FBDIX's assets and 21.8% of BIB's. They share a meaningful core but differ in the rest of the portfolio.
BIB holds far more positions (267 vs 126), so it is broader beyond the top names.
Updated Nov 22, 2026
Overlap at a glance
Holdings FBDIX and BIB have in common
| Holding | % of FBDIX | % of BIB | Overlap |
|---|---|---|---|
| Amgen, Inc. | 4.39% | 4.48% | 4.39% |
| Gilead Sciences, Inc. | 3.86% | 4.66% | 3.86% |
| Regeneron Pharmaceuticals, Inc. | 3.77% | 3.21% | 3.21% |
| Argenx SE | 3.62% | 1.19% | 1.19% |
| Vertex Pharmaceuticals, Inc. | 3.54% | 4.65% | 3.54% |
| Revolution Medicines, Inc. | 3.01% | 1.57% | 1.57% |
| Guardant Health, Inc. | 2.76% | 0.85% | 0.85% |
| Insmed, Inc. | 1.99% | 1.16% | 1.16% |
Source: SEC Form N-PORT (periods Jul 31, 2026 / May 31, 2026)
Free weekly newsletter
The Fund Letter
Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.
Free. Unsubscribe anytime. We never sell your email.
What each fund holds that the other doesn't
Top-25 holdings that appear in only one of the two funds' top 25.
Only in FBDIX
- Jazz Pharmaceuticals plc — 5.66%
- Franklin Institutional U.S. Government Money Market Fund — 3.18%
- Ascendis Pharma A/S — 2.56%
- Dianthus Therapeutics, Inc. — 2.32%
- Mirum Pharmaceuticals, Inc. — 1.98%
- Praxis Precision Medicines, Inc. — 1.91%
- Spyre Therapeutics, Inc. — 1.87%
- Oruka Therapeutics, Inc. — 1.86%
- Neurocrine Biosciences, Inc. — 1.82%
- Bridgebio Pharma, Inc. — 1.67%
- PTC Therapeutics, Inc. — 1.65%
- AstraZeneca plc — 1.51%
- Franklin Institutional U.S. Government Money Market Fund — 1.45%
- Amylyx Pharmaceuticals, Inc. — 1.32%
- Eli Lilly & Co. — 1.31%
Only in BIB
- N/a — 7.35%
- ProShares GENIUS Money Market ETF — 6.80%
- N/a — 3.94%
- N/a — 3.26%
- N/a — 2.62%
- Alnylam Pharmaceuticals, Inc. — 2.01%
- Biogen, Inc. — 1.44%
- Repurchase Agreement — 1.28%
- Illumina, Inc. — 1.25%
- United Therapeutics Corp. — 1.22%
- Royalty Pharma plc — 1.20%
- N/a — 1.18%
- Roivant Sciences Ltd. — 1.08%
- Incyte Corp. — 0.97%
- Viatris, Inc. — 0.94%
Asset mix
| Asset type | FBDIX | BIB |
|---|---|---|
| Stocks | 97.0% | 63.0% |
| Equity derivatives | — | 16.0% |
| Other | 0.6% | 6.8% |
| Cash & short-term funds | 4.6% | 0.8% |
| Repurchase agreements | — | 3.1% |
| Preferred stock | 1.0% | — |
Source: SEC Form N-PORT (periods Jul 31, 2026 / May 31, 2026)
Country mix
| Country | FBDIX | BIB |
|---|---|---|
| US | 82.0% | 79.8% |
| IE | 6.7% | 1.2% |
| NL | 4.5% | 1.6% |
| DK | 2.6% | 0.8% |
| FR | 1.7% | 1.0% |
| GB | 1.5% | 1.7% |
| CA | 1.3% | 0.6% |
| CH | 1.2% | 0.8% |
Source: SEC Form N-PORT (periods Jul 31, 2026 / May 31, 2026)
Check another pair
FAQ
How much do FBDIX and BIB overlap?
What stocks do FBDIX and BIB have in common?
Should I own both FBDIX and BIB?
Which holds more stocks, FBDIX or BIB?
Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.